ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
3 Irish finance experts on the best ways to lead your business
Emer Lyons, VP of Finance, shares her learnings and top takeaways for navigating the post-COVID economy.
How healthcare can develop through digital innovation
Gerard Quinn and Barbara Skerritt offer their insights into the rapid acceleration of digital innovation in clinical research in the past two years.
ICON says Russia’s invasion may disrupt clinical trials underway in Ukraine
This article features commentary from Steve Cutler on the impact of the war in Ukraine on clinical trials in the region.
Continuing the fight against antimicrobial resistance
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on the necessary actions to combat the threat of AMR.
Health technology assessments: understanding the global landscape and considerations for drug development
Manpreet Sidhu and Ben Cieply share insights on how HTAs inform decisions for market access and reimbursement of new pharmacotherapies.
Will big tech dominate healthcare in the years ahead?
Louisa Roberts, VP of Corporate Development and Partnerships, considers the benefits of partnerships with tech companies.
Identifying integrated digital platforms designed for a decentralised future
Matt Harrington explores how the use of digital platforms and associated services can contribute to more adaptable, accessible and efficient clinical trials.
Patient centricity in insulin injection: Using technology to improve self-administration
David T. Novotny considers the current and future developments in injection technology.
Putting patients at the heart of clinical trials
Scott Palmese, Senior Director, Accellacare Site Network, shares his insights on optimising the patient experience within clinical trials, and the ramifications of the COVID-19 pandemic.
Embedded blended solutions - A new way to optimise clinical trial portfolio delivery
John Barry and Brian Swindley offer their insights on the options available to pharma companies when delivering their clinical trial portfolios.